Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC

Published:2024-08 Issue:6 Volume:1870 Page:167249
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

Shiba-Ishii Aya,Isagawa Takayuki,Shiozawa Toshihiro,Mato Naoko,Nakagawa Tomoki,Takada Yurika,Hirai Kanon,Hong Jeongmin,Saitoh Anri,Takeda Norihiko,Niki Toshiro,Murakami Yoshinori,Matsubara Daisuke

Funder

Takeda Science Foundation

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Reference45 articles.

1. Global patterns of cancer incidence and mortality rates and trends;Jemal;Cancer Epidemiol. Biomarkers Prev.,2010

2. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023

3. KIF5B-RET fusions in lung adenocarcinoma;Kohno;Nat. Med.,2012

4. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies;Lipson;Nat. Med.,2012

5. RET, ROS1 and ALK fusions in lung cancer;Takeuchi;Nat. Med.,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP